Biopool International Inc., a Ventura producer of test kits for diagnosing blood disorders, says it has acquired a new technology for the early detection of potential complications in patients receiving heparin, a drug used in treating blood-clot diseases.
The complication may occur in as many as 10% of patients who receive the drug. The new technology was developed at the University of Alberta Hospitals in Alberta, Canada.
Biopool plans to manufacture and market the new kit, which provides results within an hour.
The market for the kit is not known, but it is less cumbersome than equivalent tests now being used, Biopool said.